Invitrogen™ CD276 (B7-H3) Recombinant Rat Monoclonal Antibody (M3.2D7)

Description

Recombinant rat monoclonal antibodies are produced using in vitro expression systems. Recombinant antibodies are produced using specific genes that code for the desired antibodies. These genes are cloned into an expression vector and expressed in vitro. The advantages of recombinant antibodies include: better specificity, lot-to-lot consistency, and broader immunoreactivity to diverse targets due to a larger rabbit immune repertoire. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

CD276 is a member of the B7 family of co-stimulatory molecules also known as B7-H3. CD276 is a type I transmembrane protein that induces the proliferation of CD4+ and CD8+ T cells, enhances the generation of cytotoxic T cells and selectively stimulates the production of interferon gamma. Expression of CD276 can be induced on dendritic cells and monocytes by inflammatory cytokines, and is also widely expressed in peripheral tissues including the heart, kidney, testis and colon. In humans, CD276 exists as two isoforms which result from gene duplication and differential splicing. CD276 is reported to have therapeutic potential for the regulation of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy.